LONDON (dpa-AFX) - AstraZeneca's (AZN.L, AZN) sipavibart demonstrated a
statistically significant reduction in the incidence of symptomatic COVID-19
compared to control (tixagevimab/cilgavimab or placebo) in an immunocompromised
patient population, as per the SUPERNOVA Phase III COVID-19 pre-exposure
prophylaxis (prevention) trial results.

The company noted that the trial met both dual primary endpoints; the first one
being the relative risk reduction of symptomatic COVID-19 caused by any
SARS-CoV-2 variant and the second being the relative risk reduction of
infections caused by SARS-CoV-2 variants not containing the F456L mutation.

The company said SUPERNOVA demonstrated the potential benefit of sipavibart in
an evolving variant landscape in which COVID-19 cases captured over the course
of the trial were caused by several different SARS-CoV-2 variants.

Sipavibart (formerly AZD3152) is an investigational long-acting monoclonal
antibody against COVID-19. Sipavibart was designed to provide broad and potent
coverage across Omicron and ancestral viral variants by neutralising spike
protein interaction with the host receptor ACE2.

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX